Файл: Название Стр.pdf

141 4
Экстрофия мочевого пузыря
Q64.1 5
Врожденный множественный артрогрипоз
Q74.3 6
Дистрофическая дисплазия костей и позвоночника
Q77.5 7
Врожденная ломкость костей
(незавершенный остеогенез)
Q78.0 8
Врожденное отсутствие конечностей
Q73.0 9
Краниосиностоз
Q75.0
ТРАВМЫ, ОТРАВЛЕНИЯ И НЕКОТОРЫЕ ДРУГИЕ ВОЗДЕЙСТВИЯ ВНЕШНИХ ПРИЧИН
1
Травмы матки, при которых невозможна имплантация эмбрионов или вынашивание беременности
S37.6
Вопрос о возможности и видах ВРТ после коррекции решается консилиумом врачей

142

143
Показатели хорошего качества работы лаборатории ВРТ
Показатель
Достаточный
уровень
«Золотой»
стандарт
Доля полученных ооцитов (ооциты/фолликулы)
-
80-95%
Доля зрелых ооцитов (ооциты MII/все ооциты)
-
75-90%
Доля прогрессивно подвижных сперматозоидов после обработки эякулята
90%
95%
Доля полиспермии после ЭКО
(3PN/инсеминированные ОКК)
<6%
<6%
Доля 1PN после ЭКО (1PN/ инсеминированные ОКК)
<5%
<5%
Доля 1PN после ИКСИ (1PN/инжектированные MII)
< 3%
< 3%
Доля бластоцист хорошего качества на 5-й день
(бластоцисты/2PN)
≥ 30%
≥ 40%
Доля оплодотворения после ЭКО (2PN/полученные ОКК)
≥ 60%
≥ 75%
Доля оплодотворения после ИКСИ
(2PN/полученные ОКК)
≥ 60%
≥ 75%
Отсутствие оплодотворения в цикле (циклы с отсутствием оплодотворения/все циклы со стимуляцией)
< 5%
< 5%
Доля дегенерации после ИКСИ
(дегенерированные MII/ инжектированные MII)
≤ 10%
≤ 5%
Процент дробления на 2-й день
(делящиеся эмбрионы/2PN)
≥ 95%
≥ 99%
Доля развития на 2-й день
(эмбрионы с 4 бластомерами/2PN)
≥ 50%
≥ 80%
Доля развития на 3-й день
(эмбрионы с 8 бластомерами/2PN)
≥ 45%
≥ 70%
Доля развития на 5-й день (бластоцисты/2PN)
≥ 40%
≥ 60%
Доля успешности биопсий
(образцы с прошедшей амплификацией/все образцы)
≥ 90%
≥ 95%
Доля выживания оттаянных бластоцист (выжившие бластоцисты/все размороженные бластоцисты)
≥ 90%
≥ 99%
Доля имплантации дробящихся эмбрионов
(число плодных яиц по данным УЗИ/число перенесенных эмбрионов)
≥ 25%
≥ 35%
Доля имплантации бластоцист
(число плодных яиц по данным УЗИ/число перенесенных бластоцист)
≥ 35%
≥ 60%

144
Список литературы
1.
Jungwirth A, Diemer T, Kopa Z. Male Infertility. EAU guidelines. 2016.
2.
Чалый МЕ, Ахвледиани НД, Харчилава РР. Мужское бесплодие. Российские клинические рекомендации. Урология. 2016;(1):2–16.
3.
World Health Organization. WHO laboratory manual for the examination and processing of human semen - 5th ed. 2010. 287 p.
4.
Баранов ВС, Кузнецова ТВ. Цитогенетика эмбрионального развития человека: Научно- практические аспекты. Издательст. СПб; 2006. 640 p.
5.
Гинтер ЕК ПВ. Наследственные болезни. Национальное руководство. Краткое издание. ГЭОТАР-Мед. Москва; 2017. 464 p.
6.
Strandell A, Lindhard A, Eckerlund I. Cost--effectiveness analysis of salpingectomy prior to
IVF, based on a randomized controlled trial. Hum Reprod [Internet]. 2005;20(12):3284–92.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/16096324 7.
Noventa M, Gizzo S, Saccardi C, Borgato S, Vitagliano A, Quaranta M, et al. Salpingectomy before assisted reproductive technologies: a systematic literature review. J Ovarian Res
[Internet]. 2016;9(1):74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27809927 8.
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam
ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril [Internet].
2012;97(1):28--38.e25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22153789 9.
Адамян ЛВ, Андреева ЕН, Аполихина ИА, Беженарь ВФ, Геворкян МА, Гус АИ, et al.
Эндометриоз: диагностика, лечение и реабилитация. Клинические рекомендации МЗ
РФ. Москва; 2013. 89 p.
10.
Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, et al.
ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014
Mar;29(3):400–12.
11.
Levine D, Brown DL, Andreotti RF, Benacerraf B, Benson CB, Brewster WR, et al.
Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of
Radiologists in Ultrasound Consensus Conference Statement. Radiology [Internet].
2010;256(3):943–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20505067 12.
Einarsson S, Bergh C, Friberg B, Pinborg A, Klajnbard A, Karlström P-O, et al. Weight reduction intervention for obese infertile women prior to IVF: a randomized controlled trial.
Hum Reprod. 2017;32(8):1621–30.
13.
Mushtaq R, Pundir J, Achilli C, Naji O, Khalaf Y, El-Toukhy T. Effect of male body mass index on assisted reproduction treatment outcome: an updated systematic review and meta- analysis. Reprod Biomed Online [Internet]. 2018;36(4):459–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29452915 14.
O’Flynn N. Assessment and treatment for people with fertility problems: NICE guideline. Br
J
Gen
Pract
[Internet].
2014;64(618):50–1.
Available from: http://bjgp.org/lookup/doi/10.3399/bjgp14X676609 15. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. Hum Reprod Update [Internet]. 18(2):111. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22301671 16.
Weigert M, Krischker U, Pöhl M, Poschalko G, Kindermann C, Feichtinger W. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing

145 hormone agonist protocol: a prospective, randomized study. Fertil Steril [Internet].
2002;78(1):34–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12095487 17.
Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol).
Reprod
Biomed
Online
[Internet].
2014;29(6):684–91.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/25444501 18.
Gupta S, Satwik R, Majumdar A, Mittal S, Tiwari N. Clomiphene based ovarian stimulation in a commercial donor program. J Hum Reprod Sci [Internet]. 8(3):142–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26538856 19.
Gibreel A, Maheshwari A, Bhattacharya S. Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization.
Cochrane database Syst Rev. 2012;11:CD008528.
20.
Mochtar MH, Danhof NA, Ayeleke RO, Van der Veen F, van Wely M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane database Syst Rev. 2017;5:CD005070.
21.
Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Bühler K, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review.
Fertil
Steril
[Internet].
2018;109(4):644–64.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/29653717 22.
Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, et al.
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane database Syst Rev. 2018;2:CD012693.
23.
Вспомогательные репродуктивные технологии (ВРТ). Рекомендации для врачей. 2007.
60 p.
24.
Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ.
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
Cochrane database Syst Rev. 2016;4:CD001750.
25.
Tang H, Mourad S, Zhai S-D, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane database Syst Rev. 2016;11:CD008605.
26.
Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560–79.
27.
Practice Committee of the American Society for Reproductive Medicine. Electronic address:
ASRM@asrm.org, Practice Committee of the American Society for Reproductive Medicine.
Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.
Fertil
Steril
[Internet].
2016;106(7):1634–47.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/27678032 28.
Wang R, Lin S, Wang Y, Qian W, Zhou L. Comparisons of GnRH antagonist protocol versus
GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis. PLoS One [Internet]. 2017;12(4):e0175985. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28437434 29.
Youssef MAFM, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen
M, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Cochrane database
Syst
Rev.
2014;(10):CD008046.
30.
Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of

146 gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective rando. Fertil Steril
[Internet].
2008;89(1):84–91.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/17462639 31.
Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online [Internet]. 2009;19(4):486–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19909588 32.
Улезко-Строгонова КП. Къ вопросу о тончайшемъ строении децидуальной ткани, ее гистогенезъ, значенiи и месте развития въ половомъ аппарате женщины. Ж
Акушерства и женскихъ болезней. 1908;(7, 8).
33.
Никитин АИ. Комментарий к статье В.С. Корсака «К вопросу о роли эндометрия в имплантации эмбрионов». Проблемы репродукции. 2016;22(3):127–8.
34.
Kasius A, Smit JG, Torrance HL, Eijkemans MJC, Mol BW, Opmeer BC, et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod
Update
[Internet].
20(4):530–41.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24664156 35.
Check JH, Cohen R. Live fetus following embryo transfer in a woman with diminished egg reserve whose maximal endometrial thickness was less than 4 mm. Clin Exp Obstet Gynecol
[Internet].
2011;38(4):330–2.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22268267 36.
Jimenez PT, Schon SB, Odem RR, Ratts VS, Jungheim ES. A retrospective cross-sectional study: fresh cycle endometrial thickness is a sensitive predictor of inadequate endometrial thickness in frozen embryo transfer cycles. Reprod Biol Endocrinol [Internet]. 2013;11:35.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/23663223 37.
Simon A, Laufer N. Assessment and treatment of repeated implantation failure (RIF). J
Assist
Reprod
Genet
[Internet].
2012;29(11):1227–39.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22976427 38.
Chen S-L, Wu F-R, Luo C, Chen X, Shi X-Y, Zheng H-Y, et al. Combined analysis of endometrial thickness and pattern in predicting outcome of in vitro fertilization and embryo transfer: a retrospective cohort study. Reprod Biol Endocrinol [Internet]. 2010;8:30.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20334664 39.
Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod
[Internet].
2010;25(10):2496–500.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20729538 40.
Duffy JM, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane database Syst Rev [Internet]. 2010;(1):CD000099. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20091500 41.
Farquhar C, Rombauts L, Kremer JA, Lethaby A, Ayeleke RO. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques.
Cochrane database
Syst
Rev.
2017;5:CD006109.
42.
Chang FE, Beall SA, Cox JM, Richter KS, DeCherney AH, Levy MJ. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation

147 and management of inadequate response. Fertil Steril [Internet]. 2016;106(5):1093--1100.e3.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/27341988 43.
Garcia-Velasco JA, Fatemi HM. To pill or not to pill in GnRH antagonist cycles: that is the question! Reprod Biomed Online [Internet]. 2015;30(1):39–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25447926 44.
Reichman DE, Chung P, Meyer L, Greenwood E, Davis O, Rosenwaks Z. Consecutive gonadotropin-releasing hormone-antagonist in vitro fertilization cycles: does the elapsed time interval between successive treatments affect outcomes? Fertil Steril [Internet]. 2013
Apr;99(5):1277–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23290740 45.
Caligara C, Navarro J, Vargas G, Simón C, Pellicer A, Remohí J. The effect of repeated controlled ovarian stimulation in donors. Hum Reprod [Internet]. 2001 Nov;16(11):2320–3.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11679512 46.
Higgins C, Healey M, Jatkar S, Vollenhoven B. Interval between IVF stimulation cycle and frozen embryo transfer: Is there a benefit to a delay between cycles? Aust N Z J Obstet
Gynaecol
[Internet].
2018
Apr;58(2):217–21.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/28905357 47.
Wikland M, Blad S, Bungum L, Hillensjö T, Karlström PO, Nilsson S. A randomized controlled study comparing pain experience between a newly designed needle with a thin tip and a standard needle for oocyte aspiration. Hum Reprod [Internet]. 2011;26(6):1377–83.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21467200 48.
Weiss A, Neril R, Geslevich J, Lavee M, Beck-Fruchter R, Golan J, et al. Lag time from ovulation trigger to oocyte aspiration and oocyte maturity in assisted reproductive technology cycles: a retrospective study. Fertil Steril [Internet]. 2014;102(2):419–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24880653 49.
Nargund G, Reid F, Parsons J. Human chorionic gonadotropin-to-oocyte collection interval in a superovulation IVF program. A prospective study. J Assist Reprod Genet [Internet].
2001;18(2):87–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11285986 50.
Bjercke S, Tanbo T, Dale PO, Abyholm T. Comparison between two hCG-to-oocyte aspiration intervals on the outcome of in vitro fertilization. J Assist Reprod Genet [Internet].
2000;17(6):319–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11042828 51.
Mansour RT, Aboulghar MA, Serour GI. Study of the optimum time for human chorionic gonadotropin-ovum pickup interval in in vitro fertilization. J Assist Reprod Genet [Internet].
1994;11(9):478–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7633170 52.
Wang W, Zhang X-H, Wang W-H, Liu Y-L, Zhao L-H, Xue S-L, et al. The time interval between hCG priming and oocyte retrieval in ART program: a meta-analysis. J Assist Reprod
Genet
[Internet].
2011;28(10):901–10.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21792666 53.
Levy G, Hill MJ, Ramirez CI, Correa L, Ryan ME, DeCherney AH, et al. The use of follicle flushing during oocyte retrieval in assisted reproductive technologies: a systematic review and meta-analysis. Hum Reprod [Internet]. 2012;27(8):2373–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22647450 54.
Farquhar C, Rishworth JR, Brown J, Nelen WLDM, Marjoribanks J. Assisted reproductive technology: an overview of Cochrane Reviews. Cochrane database Syst Rev [Internet].
2015;(7):CD010537. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26174592 55.
Glujovsky D, Farquhar C, Quinteiro Retamar AM, Alvarez Sedo CR, Blake D. Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology. Cochrane database Syst Rev. 2016;(6):CD002118.

148 56.
Phillips SJ, Dean NL, Buckett WM, Tan SL. Consecutive transfer of day 3 embryos and of day 5-6 blastocysts increases overall pregnancy rates associated with blastocyst culture. J
Assist
Reprod
Genet
[Internet].
2003;20(11):461–4.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/14714825 57.
Practice Committee of the American Society for Reproductive Medicine. Electronic address:
ASRM@asrm.org, Practice Committee of the American Society for Reproductive Medicine.